[ad_1]
Tuesday, 08.03.2022 12:31 from ARIVA.DE | Views: 42 A candlestick chart comparison (icon image). pixabay.com Trade CompuGroup Medical shares permanently for 0 euros! Now on Smartbroker.de The share certificate from CompuGroup Medical (CompuGroup Medical share) is listed lighter on Tuesday. The security last cost 45.66 euros. The CompuGroup Medical share is currently at a discount of 3.14 percent. The share fell by 1.48 euros. The paper is currently valued on the stock market at EUR 45.66. Compared to the market as a whole, CompuGroup Medical’s stock does not fare so well. The TecDAX (TecDAX ) is currently 1.23 percent down on the previous day’s closing price. He gets 2,960 points. CompuGroup Medical’s price today is by no means the lowest in the history of the paper. The security was worth exactly 35.33 euros less on March 6, 2012.
The company CompuGroup Medical
CompuGroup Medical SE & Co. KGaA is one of the leading eHealth companies in Europe. With its software and communication solutions, the company helps doctors, dentists, hospitals, associations and networks as well as other service providers to organize their workflows, to diagnose and to treat patients. CompuGroup Medical intends to announce the latest business figures on March 24, 2022.
The comparison with the peer group
CompuGroup Medical competes with a number of companies on the market. For example, the ADVA Optical Network share (ADVA Optical Network share) is currently in positive territory, unlike the CompuGroup Medical share. ADVA Optical Network gained 0.83 percent. Competitor Athenahealth’s paper (Athenahealth stock) was less in demand. The Athenahealth price remains barely moved at 0.00 percent. Continue reading
This is how analysts see the CompuGroup Medical share
The CompuGroup Medical share was recently analyzed. Baader Bank has left the rating for Compugroup ahead of figures for the fourth quarter at “Buy” with a target price of EUR 72. Despite the hacker attack, the software group should have performed well at the operational level, analyst Knut Woller wrote in a study available on Wednesday. His positive view of the shares is supported by the fact that the company confirmed its full-year targets in mid-January. This article was standardized by ARIVA.DE using company information from Finance Base and stock analysis from dpa-AFX. Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 34 b WpHG for the analyst firm mentioned can be found here. Advertising Subscribe to more news about the InnoCan Pharma share free of charge Note: ARIVA.DE publishes analyses, columns and news from various sources in this section. ARIVA.DE AG is not responsible for content that has been posted by third parties in the “News” area of this website and does not adopt it as its own. This content can be identified in particular by a corresponding “from” label below the article heading and/or by the link “To read the full article, please click here.”; The named third party is solely responsible for this content.
Other users were also interested in this article:
[ad_2]
#Stock #market #CompuGroup #Medical #share #hold #News
